| Patents for A61P 15 - Drugs for genital or sexual disorders; Contraceptives (55,635) |
|---|
| 03/26/2002 | US6362182 Hypotensive agents; anticholesterol agents; benign prostatic hypertropic |
| 03/26/2002 | US6362178 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
| 03/26/2002 | US6361778 Carboxyl terminal of papillomavirus L1 region is not required for formation of virus-like particles |
| 03/26/2002 | CA2097740C Product and process for treating bovine mastitis and bovine metritis |
| 03/26/2002 | CA2032498C Novel 8-substituted-2-aminotetralines |
| 03/21/2002 | WO2002022659A2 DISCRIMINATION BETWEEN GnRH-I AND GnRH-II |
| 03/21/2002 | WO2002022630A1 Purine derivatives |
| 03/21/2002 | WO2002022621A2 INTERPHENYLENE 7-OXABICYCLIC[2.2.1]HEPTANE OXAZOLES AS PROSTAGLANDIN F2a ANTAGONISTS |
| 03/21/2002 | WO2002022620A2 Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin f2$g(a) antagonists |
| 03/21/2002 | WO2002022610A1 Isoxazoles and their use as inhibitors of erk |
| 03/21/2002 | WO2002022585A1 Tetrahydroquinoline compounds |
| 03/21/2002 | WO2002022573A2 Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies |
| 03/21/2002 | WO2002022572A2 Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission) |
| 03/21/2002 | WO2002022561A1 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | WO2002022558A2 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | WO2002022170A1 Insulin secretion controlling agents |
| 03/21/2002 | WO2002022166A2 Tweak receptor agonists as anti-angiogenic agents |
| 03/21/2002 | WO2002022132A2 Novel topical oestroprogestational compositions with systemic effect |
| 03/21/2002 | WO2002022114A2 Methods and compositions for the treatment and prevention of sexual dysfunction |
| 03/21/2002 | WO2002022110A2 Contraception process and administration form for the same |
| 03/21/2002 | WO2002022108A1 Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor |
| 03/21/2002 | WO2001087846A3 Tricyclic pyrazole derivatives as protein kinase inhibitors |
| 03/21/2002 | WO2001068125A3 Methods and compositions for the treatment and prevention of erectile dysfunction |
| 03/21/2002 | WO2001068074A3 Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds |
| 03/21/2002 | WO2001066099A3 Use of quinazoline derivatives as angiogenesis inhibitors |
| 03/21/2002 | WO2001064837A3 β NETRIN AND USES THEREOF |
| 03/21/2002 | WO2001064165A3 Il-8 receptor antagonists |
| 03/21/2002 | WO2001062725A3 Methods and compositions for inhibiting angiogenesis |
| 03/21/2002 | WO2001055106A3 Novel melanocortin receptor agonists and antagonists |
| 03/21/2002 | WO2001051638A3 Drug metabolizing enzymes |
| 03/21/2002 | WO2001051055A3 Pharmaceutical compositions containing steroidal structures and uses thereof |
| 03/21/2002 | US20020035735 Reproducing and animal; obtain preferential embryonic cells, culture cells, transfer cells to primate, recover infant |
| 03/21/2002 | US20020035131 Administering paroxetine |
| 03/21/2002 | US20020035122 8-azabicyclo[3.2.1]oct-2-ene and -octane derivatives |
| 03/21/2002 | US20020035114 Substituted dimeric compounds |
| 03/21/2002 | US20020035110 Treatment or prevention of disorders of the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, and sleep apnea |
| 03/21/2002 | US20020035104 Integrin receptor inhibitors |
| 03/21/2002 | US20020035099 That are antagonists of the progesterone receptor, in a female contraceptive kit |
| 03/21/2002 | US20020035074 Administering isoflavone formononetin, or isoflavone daidzein |
| 03/21/2002 | US20020034557 Borage seed oil, Angelica pubescens root, Coleus forskohlii extract, vinpocetine, ferulic acid, magnesium, ascorbyl palmitate, capric/caprylic triglyceride, and silica; topical |
| 03/21/2002 | CA2432780A1 Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin f25g(a) antagonists |
| 03/21/2002 | CA2422586A1 Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies |
| 03/21/2002 | CA2422376A1 Isoxazoles and their use as inhibitors of erk |
| 03/21/2002 | CA2422246A1 Methods and compositions for the treatment and prevention of sexual dysfunction |
| 03/21/2002 | CA2422233A1 Interphenylene 7-oxabicyclic[2.2.1]heptane oxazoles as prostaglandin f2aantagonists |
| 03/21/2002 | CA2422137A1 Tetrahydroquinoline compounds |
| 03/21/2002 | CA2422095A1 Tweak receptor agonists as anti-angiogenic agents |
| 03/21/2002 | CA2422055A1 Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission) |
| 03/21/2002 | CA2421279A1 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | CA2420450A1 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | CA2391162A1 Novel topical oestroprogestational compositions with systemic effect |
| 03/20/2002 | EP1188444A1 FSH and FSH variant formulations, products and methods |
| 03/20/2002 | EP1188442A2 Cinnamomi and poria composition, method to prepare the same and uses thereof |
| 03/20/2002 | EP1187849A1 Meth1 and meth2 polynucleotides and polypeptides |
| 03/20/2002 | EP1187836A1 Substituted imidazothiazoles as antidepressant agents |
| 03/20/2002 | EP1187830A1 Process for the preparation of paroxetine and structurally related compounds |
| 03/20/2002 | EP1187627A2 Uses of h-trek-1 polypeptides and polynucleotides encoding them |
| 03/20/2002 | EP1187618A1 Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use |
| 03/20/2002 | EP1187614A1 Substituted piperidines as melanocortin-4 receptor agonists |
| 03/20/2002 | EP1090029B1 14,15-cyclopropanosteroids of the 19-norandrostane series, method for the production thereof and pharmaceutical preparations containing said compounds |
| 03/20/2002 | EP0642351B1 New pharmaceutical uses of krill enzymes |
| 03/20/2002 | CN1081063C Fetus-protecting instant particles for treating habitual or threatened abortion |
| 03/20/2002 | CN1081043C Traditional Chinese medicine capsule 'Taibao' and its preparing process |
| 03/19/2002 | US6359181 Cyclopentane 1-hydroxy alkyl or alkenyl-2-one or 2-hydroxy derivatives as therapeutic agents |
| 03/19/2002 | US6359130 Bridged indenopyrrolocarbazoles |
| 03/19/2002 | US6358958 Arylpiperazines having activity at the serotonin 1A receptor |
| 03/19/2002 | US6358947 Tetracyclic progesterone receptor modulator compounds and methods |
| 03/19/2002 | US6358937 Administering phosphatidic acid and lipid to treat drug abuse, addiction, or withdrawal and/or alcoholism |
| 03/19/2002 | US6358920 Nonapeptide anticarcinogenic and antimetastasis agents |
| 03/19/2002 | US6358706 Nucleotide sequences coding membrane protein; for use in treatment of epilepsy, schizophrenia, depression, sleep, stress, muscle, endocrine, respiratory, fertility, contraceptive, cardiovascular disorders and atherosclerosis |
| 03/19/2002 | CA2251453C 5-arylalkyl-substituted pyrazolo(4,3-d)pyrimidine-7-ones |
| 03/19/2002 | CA2236673C (-)cis-6(s)-phenyl-5(r)-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol d-tartrate |
| 03/14/2002 | WO2002020813A2 Recombinant endothelial cell growth inhibitors derived from a mammalian plasminogen |
| 03/14/2002 | WO2002020769A1 Human and mouse targeting peptides identified by phage display |
| 03/14/2002 | WO2002020767A2 G-csf analog compositions and methods |
| 03/14/2002 | WO2002020766A2 G-csf analog compositions and methods |
| 03/14/2002 | WO2002020736A2 Proteases |
| 03/14/2002 | WO2002020526A2 Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents |
| 03/14/2002 | WO2002020495A2 Inhibitors of glycogen synthase kinase 3 |
| 03/14/2002 | WO2002020489A2 QUINOLINE INHIBITORS OF cGMP PHOSPHODIESTERASE |
| 03/14/2002 | WO2002020058A1 Preparations for oral administration |
| 03/14/2002 | WO2002019999A2 Compositions for treating sexual dysfunction, containing an no-donor and an antioxidant |
| 03/14/2002 | WO2002019997A1 Pde iii inhibitors for treating sexual dysfunction |
| 03/14/2002 | WO2001064668A3 1,3-dihydro-2h-indol-2-one, and their use as v1b or both v1b and v1a arginine-vasopressin ligand receptors |
| 03/14/2002 | WO2001062737A3 Amino pyrazole derivatives useful for the treatment of obesity and other disorders |
| 03/14/2002 | WO2001055392A3 Nuclear hormone receptors |
| 03/14/2002 | WO2001055134A3 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vassopressin receptors |
| 03/14/2002 | WO2001055130A3 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors |
| 03/14/2002 | WO2001021194A3 Method for the therapeutic management of endometriosis and fallopian tube obstruction |
| 03/14/2002 | US20020032332 Hypotensive agents, antiallergens, antiasthma, treating bronchospasm, dysmenorrhea, esophageal spasm, glaucoma, premature labor, urinary tract disorder, gastrointestinal motility or cardiovascular disorders |
| 03/14/2002 | US20020032234 First fatty acid compound that is a linoleic or linolenic compound and a second fatty acid that is a docosahexaenoic acid compound, an omega-3 or an omega-2 fatty acid or derivative |
| 03/14/2002 | US20020032228 Inhibiting adenylate cyclase with a composition comprising an amount of a heterocycle-containing compound (e.g., imidazole, Celebrex or DuP-697) effective to inhibit the generation of cAMP from ATP |
| 03/14/2002 | US20020032224 Treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system disorders |
| 03/14/2002 | US20020032219 Use of alpha-1c specific compounds to treat benign prostatic hyperplasia |
| 03/14/2002 | US20020032156 Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders |
| 03/14/2002 | US20020032153 Methods and compositions for the treatment and prevention of erectile dysfunction |
| 03/14/2002 | DE10042997A1 Thienopyrimidine Thienopyrimidines |
| 03/14/2002 | CA2421922A1 Proteases |
| 03/14/2002 | CA2421760A1 G-csf analog compositions and methods |
| 03/14/2002 | CA2421757A1 G-csf analog compositions and methods |